When you think of Listerine, or of any mouthwash, what comes to mind? Anything at all? That’s the challenge in marketing oral care products: people are bored with hearing about our gum health and being shamed for our bad breath, and how else can you market mouthwash? Listerine has found a way: by marketing their product as a lifestyle. [More]
An offhanded, but definitely ill-informed, comment by View co-host Joy Behar about a nurse wearing a “doctor’s stethoscope” has resulted in one of TV’s biggest advertisers pulling its commercials from the ABC chat-fest. [More]
As we’ve previously reported, there’s a legal war going on — with optometrists and manufacturers on one side, and discount and online retailers on the other — over how much you should have to pay for your contact lenses. Both sides of this battle have recently released surveys they hope will help win over public opinion. [More]
Contact lens companies have been working together to create price floors for their products, prohibiting retailers from offering competitive discounts and removing consumers’ ability to shop around for savings. Legislators in Utah recently passed a bill that would outlaw this practice but in May a federal appeals court temporarily blocked it from being enacted. But on Friday, the court vacated that injunction, allowing the new law to move forward. [More]
In recent years, many of the country’s biggest contact lens manufacturers moved to set minimum sale prices for their products, meaning any retailer wishing to discount these lenses couldn’t go below that price floor. The practice — which would have been illegal until a 2007 Supreme Court ruling — has come under scrutiny from federal lawmakers, and Utah state legislators passed a bill earlier this year that would outlaw this form of price-fixing in the state. However, a federal appeals court has temporarily sided with the lens makers and blocked that law from being enforced. [More]
What’s a sick person to do when all the drugs on the market haven’t been able to help ease their ailment? Some of the seriously ill turn to medical trials held by drug companies to gain access to experimental drugs, but it’s not always easy to accomplish. A new system from Johnson & Johnson will employ an independent panel to review requests from seriously ill people who want to try an unapproved drug without participating in the actual testing of the drug.
Nearly five years after McNeil Consumer Healthcare – a subsidiary of Johnson & Johnson – began recalling over-the-counter Infant’s and Children’s Tylenol and Children’s Motrin, the company has acknowledged that it knowingly sold the cold medication that contained metal particles and agreed to pay $25 million to resolve the case. [More]
As anyone with bad eyesight could probably tell you, having options when it comes to the cost of contact lenses is extremely important. Just ask my fiance, because apparently I have “very expensive eyes.” I’ll take that as a compliment, but the idea that I won’t have the opportunity to find the best priced lenses next time I fill my prescription is a very real possibility, and one that’s already hurting some of the 35 million consumers who wear contacts. [More]
In the nearly decade-long history of Worst Company In America, we’ve noticed that newcomers — especially those who make the bracket because they’re in the news a lot — either flame out in the early rounds (like Lululemon) or take the tournament by storm (like past winners EA and BP). This year’s out-of-nowhere surprise comes courtesy of the folks at SeaWorld, which swam to an easy win in its WCIA debut. [More]
Recently, Johnson & Johnson reformulated their classic yellow baby shampoo after a consumer outcry over a scary-sounding formaldehyde-based preservative in the product. If it’s not absolutely necessary, there’s no good reason to go slathering a product that contains unnecessary substances on infants. The important question is: should we be worried about formaldehyde in personal-care products at all? [More]
If you asked most folks if formaldeyde sounds like a great ingredient for baby shampoo, they’d say “no.” And possibly also, “ew, gross.” Baby-goods behemoth Johnson & Johnson agrees that formaldehyde is not so much a thing your baby needs, and has rinsed it right out of their iconic yellow shampoo.
For nearly a decade, various state and federal agencies have been looking into Johnson & Johnson’s marketing of the drugs Risperdal, Invega, Natrecor, and others, claiming the company was putting consumers at risk by paying kickbacks to doctors and pharmacists to suggest these drugs to patients and for pushing unapproved uses for these medications. Today, the Justice Dept. announced that J&J will pay out more than $2.2 billion to settle these claims. [More]
At the intersection of bad marketing, inept regulation, and unwitting consumers, you’ll find the graves of young children, just some of the infants who, according to a new report from ProPublica, have become ill over the decades because Johnson & Johnson and other makers of acetaminophen-based painkillers insisted on selling two youth-targeted varieties of the drug while the FDA did what it does best — nothing. [More]
Johnson & Johnson has revealed a new bottle cap design for Tylenol products sold in the U.S. which will warn consumers in bright red lettering that the medication contains acetaminophen. The labels will alert users to the potentially fatal risks of taking too much Tylenol, which is an unusual step for a company to make. [More]
When it comes to over-the-counter pain pills, many people don’t even think to look at the expiration date on the side of the bottle. But a new class-action lawsuit claims that three of the biggest names in the (legal) drug business are deliberately putting early expiration dates on their products to encourage customers to throw them out and buy new ones. [More]
Johnson & Johnson is going forward with plans to take out any of the nasty chemicals consumers have taken issue with recently, by pledging not only to remove “chemicals of concern” from baby products by 2013, but also to reformulate adult products with safer ingredients by the end of 2015.
Desitin, the diaper rash treatment, is not a nice-smelling substance. Joyce’s husband, Ben, could tell that much before using it to treat the aftereffects of some severe gastrointestinal distress. What he didn’t realize was that the unholy stench could not be defeated. It soaked through his clothing, and when he tried to launder those clothes, the smell didn’t go away: it spread to those other items as well. Annoyed at having to toss $600 worth of clothing, the couple contacted Johnson & Johnson, seeking compensation and encouraging the company to do more to deter people who do not currently wear disposable diapers from using the product. After some letters and an offer of $75 passed in the mail, they went to small claims court. And won.
Johnson & Johnson and a subsidiary have to pay for the way it marketed antipsychotic drug Risperdal, neglecting to mention its side effects while claiming it was safer and worked better than the competition. In Arkansas, one of 11 states in which J&J has faced legal battles over the drug, a judge ordered the company to pay $1.2 billion to make up for its alleged sins.